Bio-Techne Corporation (TECH) is a Minnesota-based life sciences company with a 50-year history of serving the scientific research and diagnostics industries. The company develops and supplies ...

Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the ...

Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, ...

The approval removes one shareholder hurdle, but the transaction still depends on customary closing conditions and remaining regulatory approvals. Bio-Techne expects the deal to close in late 2026 or ...

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...